Labcorp Holdings (LH) FY2025 Earnings Quality Report

Grade: F — Cash Coverage and Goodwill Concentration

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Filed 2026-02-24) + Yahoo Finance

Auditor: Deloitte & Touche LLP — Clean opinion (1 critical audit matter: valuation of Labcorp Diagnostics segment net accounts receivable)

One-line verdict: Labcorp's F grade comes from two structural failures — $0.53B of cash covers only 8% of $6.53B of total debt, and $10.39B of goodwill plus intangibles equals 120% of the $8.62B equity base. The underlying lab-testing business is steady: revenue grew 7.2% to $13.95B, CFFO/NI of 1.87 is strong, FCF of $1.21B is healthy, gross margin widened 90bp as cost-of-revenues fell from 72.1% to 71.2% of sales, and SG&A leverage improved. The M-Score of -2.55 passes cleanly, and Debt/EBITDA of 3.2x is within the acceptable range for a diagnostics operator. This is a clean operating profile weighed down by M&A-driven balance sheet structure.

Two Segments: Diagnostics and Biopharma Laboratory Services

Labcorp reports two segments after the June 30, 2023 spin-off of Fortrea:

Diagnostics (Dx) — the clinical laboratory testing business that is the historical core of Labcorp. FY2025 revenue of $10,876.5M, up 7.2% from $10,144.3M.

Biopharma Laboratory Services (BLS) — central laboratory services for biopharmaceutical clients. FY2025 revenue of $3,098.2M, up 6.0% from $2,922.6M.

From the MD&A: "For the year ended December 31, 2025, the Company's revenues were $13,951.7, an increase of 7.2% from $13,008.9 for the corresponding period in 2024. The 7.2% increase in revenues for the year ended December 31, 2025, as compared to the corresponding period in 2024, was primarily due to organic revenue of 4.4%, acquisitions, net of divestitures of 2.5%, and favorable foreign currency translation of 0.4%."

The Dx segment growth breakdown from the MD&A: "Dx total volume, measured by requisitions, increased by 3.7%, as organic volume increased by 2.2% and acquisition volume, net of divestitures, contributed 1.5%. Price/mix increased by 3.5% due to organic growth of 1.9% and acquisitions, net of divestitures, of 1.7%, partially offset by unfavorable foreign currency translation of 0.1%."

The volume/price split is encouraging: both volume and price/mix contributed roughly equally to Dx growth, indicating sustained demand rather than pure pricing.

Cost Efficiency Improvement

From the MD&A: "Cost of revenues as a percentage of revenues decreased as a percentage of revenues to 71.2% for the year ended December 31, 2025, as compared to 72.1% for the corresponding period in 2024. This decrease was primarily due to operational efficiencies and the impact from revenue growth, including the performance of Invitae."

And: "Selling, general, and administrative expenses as a percentage of revenues decreased to 15.9% for the year ended December 31, 2025, as compared to 17.1% for the year ended December 31, 2024. The decrease was primarily due to growth in demand as the Company leveraged the growth of its revenues and a decrease in costs related to the Spin-off."

The combined 2.1pp improvement in cost of revenue plus SG&A created roughly $290M of operating leverage — visible in the jump in operating income from $1.14B to $1.52B.

Operating income grew 33% on 7.2% revenue growth — that operating leverage is the story of FY2025.

Cash Flow and Capital Resources

CFFO of $1.64B and FCF of $1.21B represent healthy cash conversion — FCF covers net income by 1.38x. The CFFO/NI ratio of 1.87 reflects substantial depreciation and amortization that flows through non-cash operating adjustments.

The 18-Point Screening

Revenue Quality

All three revenue-quality checks pass cleanly. DSO held flat at 55 days, AR grew roughly in line with revenue, and CFFO grew modestly.

Expense Quality

Gross margin widened by 90bp — consistent with the MD&A disclosure that cost of revenue fell from 72.1% to 71.2% of sales. SG&A at 55% of gross profit is typical for a clinical laboratory where sales and customer service carry significant fixed overhead.

Cash Flow Quality

C4 is the primary critical fail. $0.53B of cash against $6.53B of debt produces 8% coverage — well below the 50% threshold. However, Debt/EBITDA is 3.2x, interest coverage is comfortable, and the company generates $1.21B of FCF annually. The absolute cash-to-debt ratio fails the mechanical screen but the underlying debt service capacity is adequate.

Balance Sheet

D1 fail: Goodwill of $6.79B plus other intangibles of $3.60B = $10.39B total, or 120% of the $8.62B equity base. The absolute number grew from $9.86B to $10.39B in FY2025 — a $530M increase reflecting M&A activity. The MD&A notes "Goodwill and other asset impairments" of just $4.3M in FY2025, so the growth is all from acquisitions.

M&A Risk

Beneish M-Score

Key Risks from Item 1A

1. Reimbursement pressure and payer mix. From the 10-K's first-listed risk: "Continued changes in healthcare reimbursement models and products (e.g., health insurance exchanges), changes in government payment and reimbursement systems, or changes in payer mix, including an increase in third-party benefits management and value-based payment models, could have a material adverse effect on the Company's revenues, profitability, and cash flow. The Company's diagnostic testing services are primarily billed to third parties, including MCOs, employ[ers]."

2. OBBBA — the One Big Beautiful Bill Act impact on Medicaid and ACA. From the MD&A: "On July 4, 2025, the U.S. government enacted the OBBBA, which includes provisions addressing regulations and federal funding affecting healthcare. These provisions include, but are not limited to, changes to Medicaid and the ACA, and could lead to revised regulatory requirements and reduced federal funding. As a result of these changes, the Company could experience a decline in utilization of its diagnostics testing services due to a reduction in overall insurance coverage, which may cause the Company's revenue to decrease. However, the Company currently believes any such reduction would not likely have a material impact on its results of operations in future periods. The potential impacts described above represent the Company's assessment at this time, and the Company will continue to evaluate the impact of the OBBBA on its business and operations, if any, as the legislation's provisions continue to become effective through 2028."

3. Macroeconomic and demand cyclicality. From the 10-K: "General or macro-economic factors and significant fluctuations in economic conditions in the U.S. and globally may have a material adverse effect on the Company. The Company's business depends on sustained demand for diagnostic testing and biopharma laboratory services by patients, physicians, hospitals, MCOs, CROs, pharmaceutical, biotechnology, medical device companies, and others. Significant changes in global economic conditions, inflationary pressures, and credit market volatility could negatively affect testing volumes, the demand for biopharma laboratory services, cash collections, profitability, and access to financing."

4. Personnel and labor cost pressure. "An inability to attract, retain, and develop experienced and qualified personnel, including personnel in key roles and critical positions, and increased personnel costs, could adversely affect the Company's business... In the future, if competition for the services of these professionals increases, the Company may not be able to continue to attract and retain individuals in its markets."

5. Cybersecurity incidents (historical). The 10-K notes: "In July 2018, the Company experienced a ransomwar[e]..." — a reminder that lab operators holding massive amounts of protected health information remain high-value cyber targets.

6. Dx segment AR valuation (critical audit matter). From Deloitte's opinion: "The Company recognizes Dx revenue and accounts receivable net of negotiated discounts and anticipated adjustments, including historical collection experience for each of its four payer portfolios (clients, patients, Medicare & Medicaid, and third-party). Management has a formal process to estimate implicit price concessions for uncollectable accounts. Anticipated write-offs are recorded as adjustments to revenue at an amount considered necessary to record revenue at its net realizable value... Given the significant judgment and estimates necessary to determine the net realizable value of accounts receivable related to the Dx segment, auditing such estimates required extensive audit effort and a high degree of auditor judgment when performing audit procedures and evaluating the results of those procedures."

Altman Z-Score and F-Score

Z-Score of 3.37 comfortably clears the 2.60 safe-zone threshold. The leverage is meaningful but EBITDA and working capital support the score.

Summary

Grade: F. Fifteen passing checks with two mechanical fails on cash coverage and goodwill intensity.

Labcorp runs a steady, operationally healthy laboratory testing business. The FY2025 numbers show clean execution: 7.2% revenue growth split roughly evenly between volume and price; cost of revenue improved 90bp; SG&A leveraged 120bp; operating income grew 33%; CFFO is $1.64B; FCF is $1.21B. The M-Score of -2.55 and accruals ratio of -4.2% show no manipulation signals.

The F grade comes from two mechanical failures:

The real risks per the 10-K and the critical audit matter are: (1) OBBBA-driven changes to Medicaid and ACA that could compress diagnostic testing utilization; (2) ongoing reimbursement pressure from payers and government programs; and (3) Dx segment accounts receivable valuation, where Deloitte specifically calls out the judgment involved in estimating implicit price concessions across four payer portfolios. Earnings quality is clean; balance sheet leverage is where the F grade lives.

**Disclaimer**: This report is based on Labcorp's FY2025 10-K (SEC EDGAR) and public financial data. This is NOT investment advice.

Data: SEC EDGAR 10-K (Filed 2026-02-24) + Yahoo Finance

Auditor: Deloitte & Touche LLP (Unqualified opinion, 1 critical audit matter)